Mitali Panchpuri
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Mitali Panchpuri has a total of 14 co-authors. Here are the top co-authors by number of shared publications:
- Anindya Bose
Siksha O Anusandhan (Deemed to be University), Bhubaneswar, India
1 shared publication - Hassan Abdel-Gawad
Applied Organic Chemistry Department, Chemical Industries Research Institute, National Research Centre, Dokki, Egypt
1 shared publication - Jeetendra Kumar Gupta
Department of Pharmacology, Institute of Pharmaceutical Research, GLA University, Mathura, Uttar Pradesh, India
1 shared publication - Malina Jasamai
Centre for Drug & Herbal Development, Faculty of Pharmacy, Universiti Kebangsaan Malaysia, Jalan Raja Muda Abdul Aziz
1 shared publication - Rameeja Shaik
GITAM University, India
1 shared publication - Ranjana Prakash
School of Chemistry & Biochemistry, Thapar Institute of Engineering and Technology, Patiala 147004, Punjab, India
1 shared publication
Latest Publications
- 13 August 2026
- Published by IGI Global Scientific Publishing
- p. 129-160
Microbial Markers in Colorectal Cancer Detection and Prognosis
Colorectal cancer (CRC) represents a global health challenge, with increasing incidence rates necessitating effective early detection and prognostic techniques. Recent research has identified microbial markers vital for CRC diagnostics, including Fusobacterium nucleatum and Escherichia coli. The gut microbiome plays a crucial role in tumor development and treatment approaches, with 15-20% of CRC cases showing significant changes in microbial ecosystems that serve as non-invasive biomarkers for early diagnosis and targeted therapies. Microbes like Bacteroides fragilis and Akkermansia muciniphila are linked to various CRC stages, highlighting their influence in disease progression. High levels of Fusobacterium nucleatum notably increase CRC risk, improving diagnostic precision. These microbial indicators may enhance early detection rates by 30% compared to standard methods, while advantageous taxa potentially boost survival rates by 50%. Ongoing research focuses on examining microbial communities in fecal samples to identify CRC signatures and enhance understanding of the disease.
- 13 August 2026
- Published by IGI Global Scientific Publishing
- p. 129-160
Microbial Markers in Colorectal Cancer Detection and Prognosis
Colorectal cancer (CRC) represents a global health challenge, with increasing incidence rates necessitating effective early detection and prognostic techniques. Recent research has identified microbial markers vital for CRC diagnostics, including Fusobacterium nucleatum and Escherichia coli. The gut microbiome plays a crucial role in tumor development and treatment approaches, with 15-20% of CRC cases showing significant changes in microbial ecosystems that serve as non-invasive biomarkers for early diagnosis and targeted therapies. Microbes like Bacteroides fragilis and Akkermansia muciniphila are linked to various CRC stages, highlighting their influence in disease progression. High levels of Fusobacterium nucleatum notably increase CRC risk, improving diagnostic precision. These microbial indicators may enhance early detection rates by 30% compared to standard methods, while advantageous taxa potentially boost survival rates by 50%. Ongoing research focuses on examining microbial communities in fecal samples to identify CRC signatures and enhance understanding of the disease.
- 13 August 2026
- Published by World Scientific Pub Co Pte Ltd in International Journal of Nanoscience
Revolutionizing Disease Management: Harnessing the Synergy of Nanotechnology and Phytotherapy for Therapeutic Excellence
Nanophytotherapeutics, an amalgamation of nanotechnology and phytotherapeutics, signifies a transformative paradigm in disease management. This comprehensive review explores the vast landscape of nanophytotherapeutics, focusing on its applications in diverse medical domains, including cancer, cardiovascular diseases, neurological disorders, gastrointestinal issues, dermal disorders and urogenital disorders. The synergistic integration of precisely engineered nanoparticles with phytotherapeutic agents exhibits promising potential in targeted drug delivery, enhancing bioavailability and minimizing side effects. While the field holds remarkable promise, challenges such as toxicity understanding, large-scale production, accessibility and affordability necessitate careful consideration. The review emphasizes the imperative need for robust evidence, continued research and comprehensive training for healthcare providers to ensure the ethical and successful implementation of these groundbreaking technologies in healthcare. Looking forward, recent advancements and emerging trends underscore a promising future for nanomedicine, envisioning improved therapeutic outcomes and an enhanced quality of life for patients globally. As research progresses, nanophytotherapeutics stands poised to revolutionize disease management, offering safer and more effective alternatives to conventional treatments.
- 13 August 2026
- Published by World Scientific Pub Co Pte Ltd in International Journal of Nanoscience
Revolutionizing Disease Management: Harnessing the Synergy of Nanotechnology and Phytotherapy for Therapeutic Excellence
Nanophytotherapeutics, an amalgamation of nanotechnology and phytotherapeutics, signifies a transformative paradigm in disease management. This comprehensive review explores the vast landscape of nanophytotherapeutics, focusing on its applications in diverse medical domains, including cancer, cardiovascular diseases, neurological disorders, gastrointestinal issues, dermal disorders and urogenital disorders. The synergistic integration of precisely engineered nanoparticles with phytotherapeutic agents exhibits promising potential in targeted drug delivery, enhancing bioavailability and minimizing side effects. While the field holds remarkable promise, challenges such as toxicity understanding, large-scale production, accessibility and affordability necessitate careful consideration. The review emphasizes the imperative need for robust evidence, continued research and comprehensive training for healthcare providers to ensure the ethical and successful implementation of these groundbreaking technologies in healthcare. Looking forward, recent advancements and emerging trends underscore a promising future for nanomedicine, envisioning improved therapeutic outcomes and an enhanced quality of life for patients globally. As research progresses, nanophytotherapeutics stands poised to revolutionize disease management, offering safer and more effective alternatives to conventional treatments.